AzTrials
AzTrials

Lymphatic FunctionEarly Phase 1NCT02405559

Lymphatic Occlusion Pressure in Lower Limb

A Early Phase 1 study testing Indocyanine Green in people with Lymphatic Function, run by Centre Hospitalier Universitaire Saint Pierre at 1 site in Belgium.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The lymphatic system is one of the keystones of fluid homeostasis in the interstitium. In analogy with the arterial systolic pressure, the lymphatic pressure can give us information about the functioning of the cardiovascular system and fluid exchange. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Lymphatic Function
What is being tested?
Indocyanine Green
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
32 participants
Where
1 siteBelgium
Study dates
May 2015to Dec 2015
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Healthy volunteers
  • Written informed consent signed

Who cannot join

  • Coronary disease
  • Pregnancy
  • Allergy to iodine or to shellfish
  • Breastfeeding
  • Advanced renal impairment
  • Minors
Show all 11Show fewer
  • Thyroid pathology
  • Primary and secondary lymphedema anywhere on the body
  • Oncologic history
  • Familial lymphedema
  • Previous surgery on the studied member, causing risk of a subclinical lymphedema

Trial locations and contacts

1 site in 1 country.

Jean-Paul Belgrado contact

belgrado@ulb.ac.be

Belgium1 site
  • CHU St-Pierre - Lymphology Clinic of Brussels

    Brussels, 1000

    Jean-Paul Belgrado, belgrado@ulb.ac.be

    Jean-Paul Belgrado

Other trials in Belgium

About this study

Official title: The Occlusion Pressure of Superficial Lymphatics in the Lower Extremity of Healthy Volunteers: A Near Infrared Lymphofluoroscopy Approach

The lymphatic system is one of the keystones of fluid homeostasis in the interstitium. In analogy with the arterial systolic pressure, the lymphatic pressure can give us information about the functioning of the cardiovascular system and fluid exchange. Actually, knowledge about this physiological parameter is incomplete because of the lack of technology. Former measurement techniques of the lymphatic pressure in the living healthy man were invasive and too complex to be interpreted.

The lymphatic occlusion pressure has to be clarified because lymphedema treatment, concerning the pressure to be applied on the edematous tissue is still based on controversial concepts.

Read more

On one hand, techniques such as Manual Lymphatic Drainage, sustain the necessity to apply a very low pressure in order to avoid the squeezing of superficial lymph vessels. On the other hand sustainers of Intermittent Compression Therapy advocate the necessity to apply relatively high pressure to obtain a decongesting effect. These completely opposite opinions triggered us to study lymphatic pressure more thoroughly.

Lymphofluoroscopy (emerging imaging technique in the field of lymphology) is now used since 3 years by the promoters of this study to visualize the architecture of the superficial lymphatic network and the progression of the lymph inside the highlighted vessels. This technique will be used in the present (prospective and multicentric) study to observe the effect of a pressure applied on the lower limb on the displacement of the lymph, and then to determine the occlusion pressure of the lymphatic vessels. The investigators already studied the occlusion pressure of the superficial lymphatic vessels of the upper limb in a previous study. The investigators would like to complete our results with the lower limb.

Read the detailed description

Injection of contrast agent:

Indocyanine Green (ICG) is a tricarbocyanine dye that is commonly used for hepatic, cardiovascular, plastic surgery and ophthalmology applications. It is usually injected intravenously at a dose comprised between 0.1 and 0.5 mg/kg. After administration, ICG binds to plasmatic proteins, lipoproteins and lipids, and is thereafter rapidly and completely cleared from blood by the liver. ICG is excited and emits fluorescence in the near-infrared (around 800 nm).

In this study, the investigators will suspend ICG in 25 ml pure water and subsequently diluted with pure water to reach a final concentration of 0.2 mg/ml. Each subject will receive an intradermal injection of 0.5 ml of diluted ICG (e.i. 100µg), using a hypodermic needle. The investigators will standardize the injection point and inject ICG intradermally in the first interdigital space, according to the injection method used for lymphoscintigraphy. In this way, the investigators highlight systematically the same area of the superficial lymphatic network.

Fluorescence images acquisition:

After injection, the injection sites will be covered with tape to avoid camera oversaturation, and to avoid spreading of ICG on the skin and undesirable fluorescent background on the images. To obtain fluorescence imaging of leg lymphatic flow, a near-infrared fluorescence imaging system will be used (Photo Dynamic Eye, or PDE camera from Hamamatsu Photonics - Japan). The camera is maintained in a fix position, 15 cm above the investigation field, by a holding system from Noga Tools. The amplified analogic signal is transformed into a digital signal by a converter from Terratec (Model Grabster AV 450 MX) and transferred to a monitor, which allows to visualize lymphatic network and lymph flow in real-time. Images will be recorded on a dedicated external hard disk drive Iomega, model MDHDU.

The session will take place in a dark room, to allow NIR fluorescence images acquisition.

Specific manual lymphatic drainage, developed by the first author and his team under NIRF feedback, is performed immediately after the injection, during the whole experimental session in order to be sure that the examined lymphatic vessels permanently contain lymph. The lymph is propelled with the hand of the operator from the injection point to a limit line drawn on the skin at 5 cm before the distal extremity of the transparent cuff. This optimized manual lymphatic drainage will be performed for 3 minutes in order to easily detect the superficial lymphatic vessels at the distal region of the leg and to mark the area of interest. The MLD is standardized by the first author for this experiment, and composed by a continuous and repeated sequence, executed from distal to proximal, of 3 "fill up" maneuvers realized on the injection point, succeeded by 2 "wash out" maneuvers realized from the injection point to the limit line before the cuff. Then, two fluorescent lines are drawn on the skin in a distance of 50 mm in order to limit the space of reference.

The cuff of the transparent sphygmomanometer is placed on the distal part of the leg, just above the ankle.

The sphygmomanometer is connected to a pressure meter, indicating mm of Mercury (Testo® 510 Digital Manometer precision 0.1mmHg.).

The PDE camera will be maintained perpendicularly on the major axis of the leg, at the level of the middle of the cuff.

In order to make sure that observed lymphatic vessels contain lymph, the fluorescent lymph is propelled during all the experience with the hand of the operator from the injection point to a limit line drawn on the skin at 5 cm before the distal extremity of the transparent cuff.

  • First step: as baseline we record and observe the lymphatic flow under the un-inflated cuff.
  • Second step: the cuff is inflated at 30mmHg, images are recorded during three lymph flow passages.

Three independent observers are present. They control the three passages of lymph in order to give the consent to go over to the next pressure step.

  • Third step: The investigators increase the inflated pressure in steps of 10 mmHg recording images at each increase (waiting for three passages of lymph at each step).

The experiment is completed as soon as the investigators visually note the complete stop of lymph progression under the transparent cuff. At that moment, the pressure is reduced by 10mmHg in order to validate the return of the lymph flow. After this step, the investigators observe and record images of the lymphatic vessel from the injection point up to the root of the limb.

Being tested
Indocyanine Green

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Indocyanine GreenDrug

    Also called ICG

    Intradermal injection of Indocyanine Green in the first interdigital space of the studied leg

Study groups in NCT02405559
Study groupRoleWhat they receive
Lymphatic occlusion pressure lower limbExperimentalinjection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the leg to visualize at which pressure lymph flow is interrupted.
Receives: Drug: Indocyanine Green

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Lymph flow active or not, depending on the pressure applied

    The sphygmomanometer is connected to a pressure meter, indicating mm of Mercury (Testo® 510 Digital Manometer precision 0.1mmHg.).

    Measured: 1 minute

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Apr 2015 (estimated)
  2. Study startMay 2015
  3. Primary completionDec 2015 (estimated)
  4. Study completionDec 2015 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
32 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02405559
Sponsor's protocol ID
Ly-Occl-Pressure-2
Status last verified
Mar 2015
First submitted
5 Mar 2015
Last updated
1 Apr 2015
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Indocyanine Green in people with Lymphatic Function, run by Centre Hospitalier Universitaire Saint Pierre at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 1 Apr 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jean-Paul Belgrado (belgrado@ulb.ac.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Lymph flow active or not, depending on the pressure applied (time frame: 1 minute). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in